It Looks Like The CEO Of Windlas Biotech Limited (NSE:WINDLAS) May Be Underpaid Compared To Peers

Key Insights

• Windlas Biotech's Annual General Meeting to take place on 28th of July
• Total pay for CEO Komal Gupta includes ₹21.3m salary
• The total compensation is 78% less than the average for the industry
• Over the past three years, Windlas Biotech's EPS grew by 16% and over the past three years, the total shareholder return was 328%

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

The impressive results at Windlas Biotech Limited (NSE:WINDLAS) recently will be great news for shareholders. At the upcoming AGM on 28th of July, they will get a chance to hear the board review the company results, discuss future strategy and cast their vote on any resolutions such as executive remuneration. Here we will show why we think CEO compensation is appropriate and discuss the case for a pay rise.

Check out our latest analysis for Windlas Biotech

Comparing Windlas Biotech Limited's CEO Compensation With The Industry

At the time of writing, our data shows that Windlas Biotech Limited has a market capitalization of ₹19b, and reported total annual CEO compensation of ₹21m for the year to March 2025. We note that's an increase of 29% above last year. Notably, the salary of ₹21m is the entirety of the CEO compensation.

For comparison, other companies in the Indian Life Sciences industry with market capitalizations ranging between ₹8.6b and ₹35b had a median total CEO compensation of ₹97m. This suggests that Komal Gupta is paid below the industry median.

Talking in terms of the industry, salary represented approximately 79% of total compensation out of all the companies we analyzed, while other remuneration made up 21% of the pie. At the company level, Windlas Biotech pays Komal Gupta solely through a salary, preferring to go down a conventional route. If total compensation veers towards salary, it suggests that the variable portion - which is generally tied to performance, is lower.

A Look at Windlas Biotech Limited's Growth Numbers

Windlas Biotech Limited has seen its earnings per share (EPS) increase by 16% a year over the past three years. In the last year, its revenue is up 20%.

This demonstrates that the company has been improving recently and is good news for the shareholders. It's a real positive to see this sort of revenue growth in a single year. That suggests a healthy and growing business. We don't have analyst forecasts, but you could get a better understanding of its growth by checking out this more detailed historical graph of earnings, revenue and cash flow.

Has Windlas Biotech Limited Been A Good Investment?

Most shareholders would probably be pleased with Windlas Biotech Limited for providing a total return of 328% over three years. This strong performance might mean some shareholders don't mind if the CEO were to be paid more than is normal for a company of its size.

In Summary...

Windlas Biotech pays CEO compensation exclusively through a salary, with non-salary compensation completely ignored. The company's solid performance might have made most shareholders happy, possibly making CEO remuneration the least of the matters to be discussed in the AGM. In fact, strategic decisions that could impact the future of the business might be a far more interesting topic for investors as it would help them set their longer-term expectations.

If you think CEO compensation levels are interesting you will probably really like this free visualization of insider trading at Windlas Biotech.

Of course, you might find a fantastic investment by looking at a different set of stocks. So take a peek at this free list of interesting companies.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.